NCT01067066 is a Phase 1 clinical trial of TPI 287 in Melanoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01067066?

NCT01067066 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01067066?

Interventions in NCT01067066: TPI 287, Temodar (Temozolomide).

Is NCT01067066 still recruiting?

NCT01067066 is currently terminated. Last updated 21 July 2017.

Last reviewed 2017-07-21 · How we verify

NCT01067066

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

Terminated Phase 1 Last updated 21 July 2017

What this trial tests

Phase 1 trial testing TPI 287 in Melanoma in 21 participants. Terminated before completion.

Timeline

3 February 2010

Primary endpoint
6 July 2016

6 July 2016

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	3 February 2010
Primary completion	6 July 2016
Estimated completion	6 July 2016
Sites	1 location across United States

Drugs / interventions tested

TPI 287 — full drug profile →
Temodar (Temozolomide) — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

15 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Repositioning Microtubule Stabilizing Drugs for Brain Disorders.
Varidaki A, Hong Y, Coffey ET. · · 2018 · cited 63× · PMID 30135644 · DOI 10.3389/fncel.2018.00226

Verify or expand the search:

Other trials of TPI 287

Trials testing the same drug.

NCT02187822 — Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases · Phase 1 · terminated
NCT01332630 — TPI 287 in Breast Cancer Metastatic to the Brain · Phase 2 · completed

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01067066 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 21 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01067066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing